Ra Pharmaceuticals Inc
(RARX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2017 | 03-2017 | 12-2016 | 09-2016 | 06-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 96,605 | 105,373 | 117,812 | 31,196 | N/A |
| TOTAL | $97,836 | $107,005 | $119,502 | $31,865 | $N/A |
| Non-Current Assets | |||||
| PPE Net | 6,239 | 6,215 | 5,537 | 5,673 | N/A |
| Intangibles | 412 | 429 | 445 | 461 | 0 |
| Other Non-Current Assets | 1,334 | 1,334 | 1,334 | 2,649 | 0 |
| TOTAL | $7,985 | $7,978 | $7,316 | $8,783 | $N/A |
| Total Assets | $105,821 | $114,983 | $126,818 | $40,648 | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,134 | 1,715 | 3,252 | 2,775 | 0 |
| Accrued Expenses | 3,444 | 3,204 | 3,182 | 2,735 | N/A |
| TOTAL | $7,000 | $5,307 | $6,737 | $5,729 | $N/A |
| Non-Current Liabilities | |||||
| Deferred Revenues | 422 | 388 | 303 | 219 | N/A |
| Other Non-Current Liabilities | 0 | 0 | 0 | 86,483 | 0 |
| TOTAL | $2,645 | $2,755 | $2,859 | $89,464 | $N/A |
| Total Liabilities | $9,645 | $8,062 | $9,596 | $95,193 | $N/A |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 22,610 | 22,568 | 22,546 | 22,546 | N/A |
| Common Shares | 23 | 23 | 23 | 1 | N/A |
| Retained earnings | -92,798 | -80,135 | -68,764 | -57,876 | N/A |
| TOTAL | $96,176 | $106,921 | $117,222 | $-54,545 | $N/A |
| Total Liabilities And Equity | $105,821 | $114,983 | $126,818 | $40,648 | $0 |